Celebrex returns to the tube
This article was originally published in The Tan Sheet
Executive Summary
Pfizer resumes direct-to-consumer advertising of its COX-2 inhibitor Celebrex (celecoxib) for the first time since the company agreed to suspend DTC ads for Celebrex following the release of a study showing an increase in cardiovascular risk (1"The Tan Sheet" Jan. 10, 2005, p. 6). The new ad emphasizes Celebrex's CV risk as similar to that associated with the non-steroidal anti-inflammatory drugs ibuprofen and naproxen. "If you look closer, FDA requires all these NSAID pain relievers, including Celebrex, to have the same cardiovascular warning. Any prescription NSAID, including Celebrex, may increase the risk of heart attack or stroke," the commercial states...
You may also be interested in...
Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol
Evaluation of naproxen safety should be postponed until final data from NIH's ADAPT trial is released, Cleveland Clinic cardiologist Eric Topol, MD, advocates
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.